期刊
TOXINS
卷 13, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/toxins13010058
关键词
botulinum toxin; dystonia; recombinant botulinum toxin; acetylcholine; neuromuscular blockade
Botulinum toxin has evolved from a treatment for strabismus to the first-line treatment for focal dystonia, with at least six FDA-approved formulations available for diverse indications. These formulations have varying toxo-pharmacological properties and should not be used interchangeably. Synthetic and non-clostridial sources of BoNT are also nearing clinical use, and studies on mutations in natural toxins have led to modifications in the toxo-pharmacokinetic properties of BoNTs.
Since its introduction as a treatment for strabismus, botulinum toxin (BoNT) has had a phenomenal journey and is now recommended as first-line treatment for focal dystonia, despite short-term clinical benefits and the risks of adverse effects. To cater for the high demand across various medical specialties, at least six US Food and Drug Administration (FDA)-approved formulations of BoNT are currently available for diverse labelled indications. The toxo-pharmacological properties of these formulations are not uniform and thus should not be used interchangeably. Synthetic BoNTs and BoNTs from non-clostridial sources are not far from clinical use. Moreover, the study of mutations in naturally occurring toxins has led to modulation in the toxo-pharmacokinetic properties of BoNTs, including the duration and potency. We present an overview of the toxo-pharmacology of conventional and novel BoNT preparations, including those awaiting imminent translation from the laboratory to the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据